Cercar
28/11/2025
Atogepant after anti-CGRP monoclonal antibodies failure in migraine: a multicenter real-world study of effectiveness, safety, persistence and predictors of response
Muñoz-Vendrell, A, Campoy-Díaz, S, Valín-Villanueva, P, Casas-Limón, J, Fernández-Lázaro, I, González-García, N, Santos-Lasaosa, S, Osorio, YG, Gonzalez-Martinez, A, Campdelacreu, J, Portocarrero-Sánchez, L, Sánchez, LMC, Sánchez, SMG, Pérez-de-la-parte, A, Sánchez-Mateos, NM, López-Bravo, A, Mínguez-Olaondo, A, Sánchez-Soblechero, A, Ros, AL, Hernández, CM, López, AA, Layos-Romero, A, Caronna, E, Torres-Ferrús, M, Alpuente, A, Pozo-Rosich, P, Belvís, R, Garcia-Azorin, D, Díaz-de-Terán, J, Guerrero-Peral, AL, Gago-Veiga, AB, Huerta-Villanueva, M. Atogepant after anti-CGRP monoclonal antibodies failure in migraine: a multicenter real-world study of effectiveness, safety, persistence and predictors of response. JOURNAL OF HEADACHE AND PAIN. 2025; 27(1)DOI:10.1186/s10194-025-02239-1. PMID:41315923. IF:7.900(Q1/1D).
10/11/2025
Plasma p-tau217 as a biomarker of Alzheimer's disease pathology in individuals with Down syndrome
Huber, H, Arranz, J, Arslan, B, Leuzy, A, Kittel, O, Di Molfetta, G, Benejam, B, Videla, L, Barroeta, I, Soriano, LD, Maure-Blesa, L, Rodríguez-Baz, I, Infante, JEA, Illán-Gala, I, Bejanin, A, Montoliu-Gaya, L, Lleo, A, Carmona-Iragui, M, Alcolea, D, Blennow, K, Zetterberg, H, Fortea, J, Ashton, NJ. Plasma p-tau217 as a biomarker of Alzheimer's disease pathology in individuals with Down syndrome. Nature Communications. 2025; 16(1)DOI:10.1038/s41467-025-65882-x. PMID:41213934. IF:15.700(Q1/1D).
01/11/2025
BioFace3D: An end-to-end open-source software for automated extraction of potential 3D facial biomarkers from MRI scans
Heredia-Lidón, A, Echeverry-Quiceno, LM, González, A, Hostalet, N, Pomarol-Clotet, E, Fortea, J, Fatjó-Vilas, M, Martínez-Abadías, N, Sevillano, X. BioFace3D: An end-to-end open-source software for automated extraction of potential 3D facial biomarkers from MRI scans. COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE. 2025; 271DOI:10.1016/j.cmpb.2025.109010. PMID:40818363. IF:4.800(Q1/1D).
01/11/2025
Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease
Salvadó, G, Janelidze, S, Bali, D, Dolado, AO, Therriault, J, Brum, WS, Binette, AP, Stomrud, E, Mattsson-Carlgren, N, Palmqvist, S, Coomans, EM, Teunissen, CE, van der Flier, WM, Rahmouni, N, Benzinger, TLS, Gispert, JD, Blennow, K, Dore, V, Feizpour, A, Rowe, CC, Alcolea, D, Fortea, J, Villeneuve, S, Johnson, SC, Rosa-Neto, P, Petersen, RC, Jack, CR, Schindler, SE, Suárez-Calvet, M, Ossenkoppele, R, Hansson, O. Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease. JAMA Neurology. 2025; 82(11)DOI:10.1001/jamaneurol.2025.3217. PMID:40952756. IF:21.300(Q1/1D).